SANGAMO THERAPEUTICS INC (SGMO)

US8006771062 - Common Stock

1.3  +0.17 (+15.04%)

After market: 1.34 +0.04 (+3.08%)

Fundamental Rating

2

SGMO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 564 industry peers in the Biotechnology industry. While SGMO seems to be doing ok healthwise, there are quite some concerns on its profitability. SGMO is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SGMO has reported negative net income.
SGMO had a negative operating cash flow in the past year.
In the past 5 years SGMO always reported negative net income.
In the past 5 years SGMO reported 4 times negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -165.31%, SGMO is not doing good in the industry: 87.43% of the companies in the same industry are doing better.
The Return On Equity of SGMO (-470.00%) is worse than 79.89% of its industry peers.
Industry RankSector Rank
ROA -165.31%
ROE -470%
ROIC N/A
ROA(3y)-71.61%
ROA(5y)-48.53%
ROE(3y)-141.25%
ROE(5y)-94.01%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

SGMO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

SGMO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SGMO has been increased compared to 1 year ago.
SGMO has more shares outstanding than it did 5 years ago.
SGMO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

SGMO has an Altman-Z score of -20.77. This is a bad value and indicates that SGMO is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of SGMO (-20.77) is worse than 87.25% of its industry peers.
There is no outstanding debt for SGMO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -20.77
ROIC/WACCN/A
WACC10.61%

2.3 Liquidity

A Current Ratio of 1.35 indicates that SGMO should not have too much problems paying its short term obligations.
SGMO has a Current ratio of 1.35. This is amonst the worse of the industry: SGMO underperforms 83.12% of its industry peers.
SGMO has a Quick Ratio of 1.35. This is a normal value and indicates that SGMO is financially healthy and should not expect problems in meeting its short term obligations.
SGMO's Quick ratio of 1.35 is on the low side compared to the rest of the industry. SGMO is outperformed by 82.41% of its industry peers.
Industry RankSector Rank
Current Ratio 1.35
Quick Ratio 1.35

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 48.28% over the past year.
The Revenue for SGMO has decreased by -73.80% in the past year. This is quite bad
The Revenue has been growing by 15.84% on average over the past years. This is quite good.
EPS 1Y (TTM)48.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.78%
Revenue 1Y (TTM)-73.8%
Revenue growth 3Y14.24%
Revenue growth 5Y15.84%
Sales Q2Q%425.77%

3.2 Future

The Earnings Per Share is expected to grow by 18.70% on average over the next years. This is quite good.
The Revenue is expected to grow by 10.35% on average over the next years. This is quite good.
EPS Next Y67.39%
EPS Next 2Y36.3%
EPS Next 3Y23.31%
EPS Next 5Y18.7%
Revenue Next Year-67.76%
Revenue Next 2Y-40.64%
Revenue Next 3Y-17.04%
Revenue Next 5Y10.35%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SGMO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SGMO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

SGMO's earnings are expected to grow with 23.31% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.3%
EPS Next 3Y23.31%

More info and screens

0

5. Dividend

5.1 Amount

SGMO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SANGAMO THERAPEUTICS INC

NASDAQ:SGMO (1/3/2025, 8:02:12 PM)

After market: 1.34 +0.04 (+3.08%)

1.3

+0.17 (+15.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners42.09%
Inst Owner Change0%
Ins Owners1.09%
Ins Owner Change-0.53%
Market Cap271.25M
Analysts78.57
Price Target6.46 (396.92%)
Short Float %9.66%
Short Ratio1.88
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)108.08%
Min EPS beat(2)-21.11%
Max EPS beat(2)237.26%
EPS beat(4)1
Avg EPS beat(4)40.55%
Min EPS beat(4)-30.1%
Max EPS beat(4)237.26%
EPS beat(8)3
Avg EPS beat(8)17.65%
EPS beat(12)7
Avg EPS beat(12)16.54%
EPS beat(16)8
Avg EPS beat(16)9.91%
Revenue beat(2)1
Avg Revenue beat(2)37.1%
Min Revenue beat(2)-95.77%
Max Revenue beat(2)169.98%
Revenue beat(4)1
Avg Revenue beat(4)-23.5%
Min Revenue beat(4)-95.77%
Max Revenue beat(4)169.98%
Revenue beat(8)2
Avg Revenue beat(8)47.82%
Revenue beat(12)5
Avg Revenue beat(12)33.35%
Revenue beat(16)8
Avg Revenue beat(16)24.88%
PT rev (1m)2.15%
PT rev (3m)66.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-112.5%
EPS NY rev (1m)-2.92%
EPS NY rev (3m)5.19%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-19.94%
Revenue NY rev (1m)0.36%
Revenue NY rev (3m)8.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.14
P/FCF N/A
P/OCF N/A
P/B 6.93
P/tB 6.93
EV/EBITDA N/A
EPS(TTM)-0.75
EYN/A
EPS(NY)-0.21
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS0.25
BVpS0.19
TBVpS0.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -165.31%
ROE -470%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-71.61%
ROA(5y)-48.53%
ROE(3y)-141.25%
ROE(5y)-94.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 48.33%
Cap/Sales 5.25%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.35
Quick Ratio 1.35
Altman-Z -20.77
F-Score2
WACC10.61%
ROIC/WACCN/A
Cap/Depr(3y)185.08%
Cap/Depr(5y)205.75%
Cap/Sales(3y)17.07%
Cap/Sales(5y)16.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.78%
EPS Next Y67.39%
EPS Next 2Y36.3%
EPS Next 3Y23.31%
EPS Next 5Y18.7%
Revenue 1Y (TTM)-73.8%
Revenue growth 3Y14.24%
Revenue growth 5Y15.84%
Sales Q2Q%425.77%
Revenue Next Year-67.76%
Revenue Next 2Y-40.64%
Revenue Next 3Y-17.04%
Revenue Next 5Y10.35%
EBIT growth 1Y-57.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year64.05%
EBIT Next 3Y26.79%
EBIT Next 5Y26.23%
FCF growth 1Y50.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y47.89%
OCF growth 3YN/A
OCF growth 5YN/A